Lingkang Pharmaceuticals: Wholly-owned subsidiary obtains approval notice for clinical trial of Acetazolamide Extended-release Capsules medicine

Lingkang Pharmaceutical announced that its wholly-owned subsidiary, Hainan Lingkang Pharmaceutical Co., Ltd., recently obtained the "Drug Clinical Trial Approval Notice" issued by the Drug Evaluation Center of the National Medical Products Administration for the sustained-release capsules of acetazolamide. This drug is used to prevent or improve the symptoms of acute mountain sickness that may still appear when the altitude rises gradually. Currently, no other domestic enterprises have applied for this product, and Lingkang Pharmaceutical has invested 6.9 million RMB in research and development expenses.